- Design
- Preclinical dose-ranging study in an orthologous mouse model with mechanistic signalling analysis
- Population
- Pkd1 RC/RC mice treated from 4 to 16 weeks of age with MQ232 at four doses, tolvaptan, or vehicle
- Primary outcome
- Kidney volume by MRI, with kidney cAMP, aquaporin-2 and signalling protein phosphorylation
- Effect
- MQ232 and tolvaptan attenuated disease equally; higher MQ232 doses reduced kidney cAMP and raised urine output without additional benefit, with no correlation between either and disease attenuation
Tolvaptan is the only drug approved specifically for autosomal dominant polycystic kidney disease, and it is titrated to the maximum tolerated dose on the assumption that more vasopressin V2 receptor blockade means more benefit. This study, published in May, tested that assumption using MQ232, a peptide derived from green mamba venom and optimised as a V2 receptor inverse agonist, in Pkd1 RC/RC mice.
MQ232 and tolvaptan attenuated disease equally. But in male mice, rising MQ232 doses produced progressively greater falls in kidney cAMP and greater urine output without any additional disease benefit — and there was no correlation between kidney cAMP or urine output and how much the disease was attenuated. Phosphorylation ratios for Src, ERK and several other signalling proteins fell with treatment, but that effect was blunted or reversed at higher doses.
The interpretation offered is that these compounds are dual-efficacy ligands: inverse agonists at the Gαs–cAMP pathway, but at high doses activators of β-arrestin-associated Src and ERK signalling, which is cystogenic. If that holds in humans, titrating to maximum tolerated dose would be trading a cAMP benefit for a signalling harm — and the dose-limiting aquaresis would be the least of the problem.
- Continue current tolvaptan dosing practice — this is a mouse study and does not change licensed titration.
- Note that urine output is not a marker of therapeutic effect here; it tracked dose, not disease attenuation.
- Watch for dose-ranging work in humans; this is the kind of finding that would reframe a licensed titration schedule.
- Keep monitoring liver function on tolvaptan regardless — the established hepatotoxicity signal is unaffected by any of this.
Why it matters
A drug titrated to maximum tolerated dose may be crossing the point where more blockade stops helping.
Don't overread it
This is a mouse model with mechanistic signalling data; it does not show that lower tolvaptan doses work as well in patients.
The statistics, in plain English
The key observation is an absence of correlation: kidney cAMP and urine output varied with dose while disease attenuation did not. In a small mouse study, absence of correlation can reflect insufficient power as easily as a real biological ceiling. The signalling data supporting the dual-efficacy explanation are protein phosphorylation ratios, which are several steps removed from cyst growth.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free